# Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG

> **NCT07216391** · PHASE2 · NOT_YET_RECRUITING · sponsor: **National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)** · enrollment: 60 (estimated)

## Conditions studied

- Type 1 Diabetes Mellitus

## Interventions

- **DRUG:** Antithymocyte Globulin (ATG)
- **DRUG:** Teplizumab

## Key facts

- **NCT ID:** NCT07216391
- **Lead sponsor:** National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-04-15
- **Primary completion:** 2029-11-30
- **Final completion:** 2030-05-30
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-02-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07216391

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07216391, "Platform Trial to Delay Stage 3 Diabetes: Comparing Teplizumab With ATG". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT07216391. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*